Market closed
Intellia Therapeutics/$NTLA
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Intellia Therapeutics
Intellia Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.
Ticker
$NTLA
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
403
Website
NTLA Metrics
BasicAdvanced
$748M
-
-$5.25
1.97
-
Price and volume
Market cap
$748M
Beta
1.97
52-week high
$28.18
52-week low
$5.90
Average daily volume
3.5M
Financial strength
Current ratio
5.772
Quick ratio
5.503
Long term debt to equity
21.785
Total debt to equity
24.106
Management effectiveness
Return on assets (TTM)
-26.80%
Return on equity (TTM)
-54.00%
Valuation
Price to revenue (TTM)
12.348
Price to book
0.85
Price to tangible book (TTM)
0.85
Price to free cash flow (TTM)
-2.015
Growth
Revenue change (TTM)
59.55%
Earnings per share change (TTM)
-3.14%
3-year revenue growth (CAGR)
20.53%
3-year earnings per share growth (CAGR)
11.59%
What the Analysts think about NTLA
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Intellia Therapeutics stock.
NTLA Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
NTLA Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
NTLA News
AllArticlesVideos
Shareholders of Intellia Therapeutics, Inc. Should Contact Levi & Korsinsky Before April 14, 2025 to Discuss Your Rights - NTLA
Accesswire·5 days ago
NTLA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Intellia Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
GlobeNewsWire·5 days ago
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of April 14, 2025 in Intellia Lawsuit - NTLA
Accesswire·5 days ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Intellia Therapeutics stock?
Intellia Therapeutics (NTLA) has a market cap of $748M as of April 19, 2025.
What is the P/E ratio for Intellia Therapeutics stock?
The price to earnings (P/E) ratio for Intellia Therapeutics (NTLA) stock is 0 as of April 19, 2025.
Does Intellia Therapeutics stock pay dividends?
No, Intellia Therapeutics (NTLA) stock does not pay dividends to its shareholders as of April 19, 2025.
When is the next Intellia Therapeutics dividend payment date?
Intellia Therapeutics (NTLA) stock does not pay dividends to its shareholders.
What is the beta indicator for Intellia Therapeutics?
Intellia Therapeutics (NTLA) has a beta rating of 1.97. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.